vTv Therapeutics (NASDAQ:VTVT) Share Price Crosses Below 50-Day Moving Average – Should You Sell?

vTv Therapeutics Inc. (NASDAQ:VTVT)’s share price passed below its 50-day moving average during trading on Wednesday . The stock has a 50-day moving average of $36.18 and traded as low as $32.90. vTv Therapeutics shares last traded at $35.10, with a volume of 137,888 shares changing hands.

Analyst Ratings Changes

A number of research analysts have recently commented on the company. Roth Mkm assumed coverage on vTv Therapeutics in a research note on Thursday, January 22nd. They issued a “buy” rating and a $58.00 target price for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of vTv Therapeutics in a research report on Monday, December 29th. BTIG Research reaffirmed a “buy” rating and issued a $49.00 target price on shares of vTv Therapeutics in a research report on Wednesday. TD Cowen initiated coverage on shares of vTv Therapeutics in a research report on Monday, January 5th. They set a “buy” rating for the company. Finally, HC Wainwright restated a “buy” rating and issued a $47.00 price objective (up from $36.00) on shares of vTv Therapeutics in a report on Friday, December 19th. Four analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $55.25.

vTv Therapeutics Trading Up 0.2%

The company has a market cap of $138.29 million, a P/E ratio of -10.48 and a beta of 0.44. The stock’s 50 day moving average is $36.18 and its 200-day moving average is $29.26.

vTv Therapeutics (NASDAQ:VTVT) last released its quarterly earnings data on Tuesday, March 10th. The biotechnology company reported ($0.58) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.09) by $0.51. The firm had revenue of ($0.02) million for the quarter.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the business. Goldman Sachs Group Inc. bought a new position in shares of vTv Therapeutics during the fourth quarter valued at $221,000. 683 Capital Management LLC bought a new stake in vTv Therapeutics in the 4th quarter worth about $731,000. Geode Capital Management LLC raised its position in vTv Therapeutics by 84.3% in the 4th quarter. Geode Capital Management LLC now owns 28,194 shares of the biotechnology company’s stock worth $1,128,000 after buying an additional 12,896 shares during the last quarter. Finally, Baker BROS. Advisors LP lifted its stake in vTv Therapeutics by 52.4% during the 3rd quarter. Baker BROS. Advisors LP now owns 148,314 shares of the biotechnology company’s stock valued at $3,463,000 after acquiring an additional 51,000 shares during the period. Hedge funds and other institutional investors own 17.51% of the company’s stock.

About vTv Therapeutics

vTv Therapeutics, Inc is a clinical-stage biopharmaceutical company headquartered in Westport, Connecticut, focused on discovering and developing orally administered small-molecule therapies for chronic diseases. Employing its proprietary medicinal chemistry platform, the company seeks to generate novel compounds that modulate key disease pathways while optimizing safety and pharmacokinetic properties.

The company’s lead candidate, azeliragon (TTP488), is an oral inhibitor of the receptor for advanced glycation end products (RAGE) and has completed Phase II/III clinical evaluation in early-stage Alzheimer’s disease.